Archive for April, 2015


April 10, 2015


MedicalResearch.com Interview with:
Luis Squiquera, MD
Tamir Biotechnology

MedicalResearch: What is the background for this study? What are the main findings?

Dr. Squiquera: Ranpirnase is a small peptide that has a characteristic enzymatic activity against double stranded RNA (dsRNA). As a drug it has been extensively tested intravenously in high concentration for oncology in over 1000 patients with different types of malignancy, especially mesothelioma, with minimal side effects and mainly a transient increase of serum creatinine level observed.

Read the full article here.
From medicalresearch.com

Continue reading

April 3, 2015


SAN FRANCISCO — The experimental antiviral drug ranpirnase can completely clear away the warts caused by human papillomavirus (HPV), a preliminary study has shown.

If these results are borne out in further studies, ranpirnase would be the first drug to attakc HPV itself, said Eric Daniels, MD, a research consultant for Tamir Biotechnology in San Diego.

Read the full article here. (PDF)
From www.medscape.com

Continue reading

April 1, 2015


SAN FRANCISCO — Three-fourths of men with anogenital warts caused by human papillomavirus (HPV) had clinical remission and the rest had partial responses to a frog-derived enzyme, investigators reported here.

Clinical remission occurred in 18 of 24 evaluable patients in response to ranpirnase, an endoribonuclease derived from the eggs of Rana pipiens, or Northern Leopard frog. The patients received 1 mg/mL BID of a topical formulation of ranpirnase, and remissions occurred, on average, within 33 days of starting treatment, Luis Squiquera, MD, of Tamir Biotechnology, reported at the American Academy of Dermatology meeting.

Read the full article here.
From www.medpagetoday.com

Continue reading
Back to top